Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
RESEARCH TOOLSreports
Holding AUPH?
Track your performance easily
AUPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.71 - $10.05
Previous Close$7.16
Volume128.17K
Average Volume (3M)1.45M
Market Cap
$1.03B
Enterprise Value$779.32M
Total Cash (Recent Filing)$330.48M
Total Debt (Recent Filing)$85.98M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Oct 31, 2024EPS Estimate
$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding142,990,974
10 Day Avg. Volume1,326,711
30 Day Avg. Volume1,445,387
Standard Deviation0.31
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.81
Price to Sales (P/S)4.97
Price to Cash Flow (P/CF)16.30
P/FCF Ratio15.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.76
Enterprise Value/Gross Profit4.83
Enterprise Value/Ebitda-20.22
Forecast
1Y Price Target
$10.48Price Target Upside45.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Aurinia Pharmaceuticals News
PremiumCompany Announcements
Aurinia’s Lupus Drug LUPKYNIS Wins Approval in Japan
PremiumCompany Announcements
Aurinia Pharmaceuticals Announces Board Restructuring and Director Changes
PremiumCompany Announcements
Aurinia Pharmaceuticals Begins AUR200 Autoimmune Therapy TrialBulls Say, Bears Say
Bulls Say
Financial PerformanceAurinia achieved its first quarter of sustainable positive free cash flow, ahead of management's own projection.
Regulatory ApprovalThe Japanese Health Authorities have approved Lupkynis for the treatment of lupus, which could lead to incremental revenues.
Revenue GuidanceManagement has increased the lower end of annual revenue guidance, indicating confidence in the company's financial outlook.
Bears Say
Market ExclusivityIntellectual property challenges could reduce market exclusivity, impacting long-term profitability.
Revenue GrowthRevenue growth falling short of guidance or significantly below expectations poses a major risk.
Strategic SynergiesDisappointment persists that more value could have been unlocked through strategic synergies within a larger commercial organization.
---
Ownership Overview
60.23% Insiders
5.27% Mutual Funds
22.52% Other Institutional Investors
11.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $4.71 and its highest was $10.05 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Currently, no data Available
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Oct 31, 2024 which is in 34 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Aug 01, 2024. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.002.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is $0.02.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 142,990,970 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of $0.01 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went down -4.592%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
---
Aurinia Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.48 (45.76% Upside)
$10.48 (45.76% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 97%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $96.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.36%
12-Months-Change
Fundamentals
Return on Equity
-13.30%
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
---
AUPH Earnings Call
Q2 2024
0:00 / 0:00
---
AUPH Revenue Breakdown
90.33% Product revenue, net
9.67% License and contract revenue
---
AUPH Stock 12 Month Forecast
Average Price Target
$10.48
▲(45.76% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
BioMarin Pharmaceutical
―
Bristol-Myers Squibb
―
AstraZeneca
―
Best Analysts Covering AUPH
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+31.23%
reiterated a buy rating 3 days ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +31.23% per trade.
---